{
    "nctId": "NCT04517266",
    "briefTitle": "Evaluating Omitting of Internal Mammary Irradiation Among Early Stage Intermediate Risk (N1) Breast Cancer",
    "officialTitle": "Evaluating Omitting of Internal Mammary Irradiation Among Early Stage Intermediate Risk (N1) Breast Cancer Patients According to Clinical-genomic Model: an Open Label, Non-inferior Randomized Controlled Trial",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 214,
    "primaryOutcomeMeasure": "2-year event-free survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* \u2022 Histologically confirmed invasive breast cancer\n\n  * Underwent radical surgery with either mastectomy or breast conserving surgery and axillary lymph node dissection (ALND)\n  * The number of positive lymph node should be 1-3 (N1).\n  * Clinical high risk breast cancer (\u22652 clinical risk factors)\n  * Aged 18-80 years old\n  * ECOG performance status \u22642 (Karnofsky \u226570%) Anticipative overall survival \\>5 years Pathologically surgical margin \\>2mm ER (estrogen-receptor), PR (progesterone-receptor), HER2 (human epidermal growth factor receptor 2) and Ki67 testing can be performed on the primary breast tumor Women of child-bearing potential must agree to use adequate contraception for up to 1 month before study treatment and the duration of study participation Ability to understand and willingness to participate the research and sign the consent form\n\nExclusion Criteria:\n\n* \u2022 Axillary dissection of less than 10 lymph nodes\n\n  * Pathologically positive ipsilateral supraclavicular lymph node\n  * Pathologically or radiologically confirmed involvement of ipsilateral internal mammary lymph nodes\n  * Pregnant or lactating women\n  * Treated with breast reconstruction surgery\n  * Severe non-neoplastic medical comorbidities\n  * History of non-breast malignancy within 5 years with the exception of lobular carcinoma in situ, basal cell carcinoma of the skin, carcinoma in situ of skin and carcinoma in situ of the cervix\n  * simultaneous contralateral breast cancer\n  * Previous radiotherapy to the neck, chest and/or ipsilateral axillary region\n  * Active collagen vascular disease\n  * Definitive pathological or radiologic evidence of distant metastatic disease\n  * Primary T4 tumor\n  * Interval between radical surgery (mastectomy or breast conserving surgery) and radiotherapy was more than 12 weeks or interval between last dose of adjuvant chemotherapy and radiotherapy was more than 8 weeks",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}